Literature DB >> 16034443

Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia.

Henry H Holcomb1, Adrienne C Lahti, Deborah R Medoff, Tom Cullen, Carol A Tamminga.   

Abstract

Schizophrenia may be related to dysfunctional glutamatergic activity, specifically hypofunction of the N-methyl-D-aspartate receptor (NMDAR). In addition, it has been proposed that NMDAR hypofunction may paradoxically cause an increase in glutamate release and hypermetabolism in corticolimbic regions. If a state of partial, chronic NMDAR blockade underlies schizophrenia, then schizophrenic volunteers (SV) may have greater glutamate release and associated elevations in regional cerebral blood flow (rCBF) than normal volunteers (NV), following drug-induced NMDAR antagonism. Therefore, we have given acute ketamine, a noncompetitive NMDAR antagonist, to NV (n=13) and medicated volunteers with schizophrenia (n=10) in conjunction with serial positron emission tomography blood flow studies. Drug administration caused marked rCBF elevations in frontal and cingulate regions in both groups. Contrasts between NV and SV ketamine groups showed that SV had greater relative blood flow increases in the anterior cingulate than NV. Maximum blood flow, and the area under the curve for blood flow in the anterior cingulate cortex, significantly correlated with changes in psychosis ratings in SV and NV (maximum rCBF only). These changes are consistent with a relatively hypoactive thalamic NMDAR and increased cortical glutamate neurotransmission at non-NMDARs in schizophrenia. We hypothesize that ketamine antagonizes an NMDAR-dependent inhibitory system that is partially compromised in subjects with schizophrenia. The ketamine-induced reduction of inhibition leads to a marked increase in glutamate release and hypermetabolism (elevated rCBF) in frontal and cingulate cortical regions. The loss of inhibition and increased glutamate release may cause the distorted thoughts and diminished cognitive abilities elicited by NMDAR blockade.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16034443     DOI: 10.1038/sj.npp.1300824

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  42 in total

1.  Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.

Authors:  Surendra P Singh; Vidhi Singh
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

2.  Phenomenologically distinct psychotomimetic effects of ketamine are associated with cerebral blood flow changes in functionally relevant cerebral foci: a continuous arterial spin labelling study.

Authors:  T A Pollak; S De Simoni; B Barimani; F O Zelaya; J M Stone; M A Mehta
Journal:  Psychopharmacology (Berl)       Date:  2015-10-05       Impact factor: 4.530

3.  Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study.

Authors:  Lidia Glodzik; Kevin G King; Oded Gonen; Songtao Liu; Susan De Santi; Mony J de Leon
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-02-07       Impact factor: 5.067

Review 4.  Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology.

Authors:  Alex Fornito; Murat Yücel; Brian Dean; Stephen J Wood; Christos Pantelis
Journal:  Schizophr Bull       Date:  2008-04-23       Impact factor: 9.306

Review 5.  GABA abnormalities in schizophrenia: a methodological review of in vivo studies.

Authors:  Stephan F Taylor; Ivy F Tso
Journal:  Schizophr Res       Date:  2014-10-25       Impact factor: 4.939

6.  Age-related changes in anterior cingulate cortex glutamate in schizophrenia: A (1)H MRS Study at 7 Tesla.

Authors:  Allison S Brandt; Paul G Unschuld; Subechhya Pradhan; Issel Anne L Lim; Gregory Churchill; Ashley D Harris; Jun Hua; Peter B Barker; Christopher A Ross; Peter C M van Zijl; Richard A E Edden; Russell L Margolis
Journal:  Schizophr Res       Date:  2016-02-28       Impact factor: 4.939

7.  Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist.

Authors:  Stefanie Dedeurwaerdere; Cindy Wintmolders; Roel Straetemans; Darrel Pemberton; Xavier Langlois
Journal:  Psychopharmacology (Berl)       Date:  2010-10-31       Impact factor: 4.530

8.  Ketamine induced changes in regional cerebral blood flow, interregional connectivity patterns, and glutamate metabolism.

Authors:  James Edward Bryant; Michael Frölich; Steve Tran; Meredith Amanda Reid; Adrienne Carol Lahti; Nina Vanessa Kraguljac
Journal:  J Psychiatr Res       Date:  2019-07-27       Impact factor: 4.791

9.  Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia.

Authors:  Inna Gaisler-Salomon; Gretchen M Miller; Nao Chuhma; Sooyeon Lee; Hong Zhang; Farhad Ghoddoussi; Nicole Lewandowski; Stephen Fairhurst; Yvonne Wang; Agnès Conjard-Duplany; Justine Masson; Peter Balsam; René Hen; Ottavio Arancio; Matthew P Galloway; Holly M Moore; Scott A Small; Stephen Rayport
Journal:  Neuropsychopharmacology       Date:  2009-06-10       Impact factor: 7.853

10.  Phencyclidine Discoordinates Hippocampal Network Activity But Not Place Fields.

Authors:  Hsin-Yi Kao; Dino Dvořák; EunHye Park; Jana Kenney; Eduard Kelemen; André A Fenton
Journal:  J Neurosci       Date:  2017-11-08       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.